Document:

WARRANT	 
	 	 	 
	NO.	 	________ Shares

 

WARRANT TO PURCHASE COMMON STOCK

 

VOID AFTER 5:30 P.M., EASTERN 

TIME, ON THE EXPIRATION DATE

 

THE SECURITIES FOR WHICH THIS SECURITY
IS EXERCISABLE HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN
RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND,
ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT
TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN
ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE
SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE
PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

 

FOR VALUE RECEIVED,
Ticket to See, Inc. a Nevada corporation (the “Company”), hereby agrees to sell upon the terms and on the conditions
hereinafter set forth, but no later than 5:30 p.m., Eastern Time, on the Expiration Date (as hereinafter defined) to ________________
or registered assigns (the “ Holder ”), under the terms as hereinafter set forth, __________________ (_____________)
fully paid and non-assessable shares of the Company’s common stock (the “Common Stock”), par value $0._____ per
share (the “ Warrant Stock ”), at a purchase price of $0.75 per share (the “ Warrant Price ”),
pursuant to this warrant (this “Warrant ”). The number of shares of Warrant Stock to be so issued and the Warrant
Price are subject to adjustment in certain events as hereinafter set forth. The term “Common Stock” shall mean,
when used herein, unless the context otherwise requires, the stock and other securities and property at the time receivable upon
the exercise of this Warrant.

 

1.                 
Exercise of Warrant and Redemption of Warrant.

 

a.                  
The Holder may exercise this Warrant according to its terms by surrendering this Warrant to the Company at the address set forth
in Section 10, the Notice of Exercise attached hereto having then been duly executed by the Holder, accompanied by cash, certified
check or bank draft in payment of the purchase price, in lawful money of the United States of America, for the number of shares
of the Warrant Stock specified in the Notice of Exercise, or as otherwise provided in this Warrant, prior to 5:30 p.m., Eastern
Time, on June _____, 2019 (the “ Expiration Date ”).

 

This Warrant may be
exercised in whole or in part so long as any exercise in part hereof would not involve the issuance of fractional shares of Warrant
Stock. If exercised in part, the Company shall deliver to the Holder a new Warrant, identical in form, in the name of the Holder,
evidencing the right to purchase the number of shares of Warrant Stock as to which this Warrant has not been exercised, which new
Warrant shall be signed by the Chairman, Chief Executive Officer or President and the Secretary or Assistant Secretary of the Company.
The term Warrant as used herein shall include any subsequent Warrant issued as provided herein.

 

b.                 
No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. The Company shall
pay cash in lieu of fractions with respect to the Warrants based upon the fair market value of such fractional shares of Common
Stock (which shall be the closing price of such shares on the exchange or market on which the Common Stock is then traded) at the
time of exercise of this Warrant.

 

c.                  
In the event of any exercise of the rights represented by this Warrant, a certificate or certificates for the Warrant Stock so
purchased, registered in the name of the Holder, shall be delivered to the Holder within three (3) trading days after such rights
shall have been so exercised (the “ Warrant Stock Delivery Date ”). The person or entity in whose name any certificate
for the Warrant Stock is issued upon exercise of the rights represented by this Warrant shall for all purposes be deemed to have
become the holder of record of such shares immediately prior to the close of business on the date on which the Warrant was surrendered
and payment of the Warrant Price and any applicable taxes was made, irrespective of the date of delivery of such certificate, except
that, if the date of such surrender and payment is a date when the stock transfer books of the Company are closed, such person
shall be deemed to have become the holder of such shares at the opening of business on the next succeeding date on which the stock
transfer books are open. The Company shall pay any and all documentary stamp or similar issue or transfer taxes payable in respect
of the issue or delivery of shares of Common Stock on exercise of this Warrant.

 

    	 

    	 

    

  

d.                 
In addition to any other rights available to the Holder, if the Company fails to cause its transfer agent to transmit to the Holder
a certificate or the certificates representing the Warrant Stock pursuant to an exercise on or prior to the Warrant Stock Delivery
Date, and if after such date the Holder is required by its broker to purchase (in an open market transaction or otherwise) or the
Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of
the Warrant Stock which the Holder anticipated receiving upon such exercise (a “ Buy-In ”), then the Company
shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s total purchase price (including brokerage
commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number
of shares of Warrant Stock that the Company was required to deliver to the Holder in connection with the exercise at issue times
(2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder,
either reinstate the portion of the Warrant and equivalent number of shares of Warrant Stock for which such exercise was not honored
(in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would
have been issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder
purchases Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares
of Common Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately
preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice
indicating the amounts payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount
of such loss. Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law
or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s
failure to timely deliver certificates representing shares of Common Stock upon exercise of the Warrant as required pursuant to
the terms hereof.

 

e.                  
Redemption of Warrant

 

(i)               
General. Prior to the Expiration Date, the Company shall have the option, subject to the conditions set forth herein, to
redeem all of the Warrants then outstanding upon not less than thirty (30) days nor more than sixty (60) days prior written notice
to the Warrant Holders at any time provided that, at the time of delivery of such notice (i) there is an effective registration
statement covering the resale of the Warrant Shares, and (ii) the average trading price of the Company’s Common Stock , or
shares into which the Common Stock have been exchanged, for each of the twenty (20) consecutive trading days prior to the date
of the notice of redemption is at least $2.50, as proportionately adjusted to reflect any stock splits, stock dividends, combination
of shares or like events, with an average daily trading volume during such period of 100,000 shares.

 

(ii)               
Notice. Notice of redemption will be effective upon mailing in accordance with this Section and such date may be referred
to below as the “Notice Date.” Notice of redemption shall be mailed by first class mail, postage prepaid, by
the Company not less than 30 days prior to the date fixed for redemption to the Holders of the Warrants to be redeemed at their
last addresses as they shall appear on the registration books. Any notice mailed in the manner herein provided shall be conclusively
presumed to have been duly given whether or not the Holder received such notice.

 

(iii)             
Redemption Date and Redemption Price. The notice of redemption shall state the date set for redemption, which date shall
be not less than thirty (30) days, or more than sixty (60) days, from the Notice Date (the “Redemption Date”). The
Company shall not mail the notice of redemption unless all funds necessary to pay for redemption of the Warrants to be redeemed
shall have first been set aside by the Company for the benefit of the Warrant Holders so as to be and continue to be available
therefor. The redemption price to be paid to the Warrant Holders will be $2.50 for each share of Common Stock of the Company to
which the Warrant Holder would then be entitled upon exercise of the Warrant being redeemed, as adjusted from time to time as provided
herein (the “Redemption Price”).

 

(iv)               
Exercise. Following the Notice Date, the Warrant Holders may exercise their Warrants in accordance with Section 1 of this
Warrant between the Notice Date and 5:00 p.m. Eastern Time on the Redemption Date and such exercise shall be timely if the form
of election to purchase duly executed and the Warrant Exercise Price for the shares of Common Stock to be purchased are actually
received by the Company at its principal offices prior to 5:00 p.m. Eastern Time on the Redemption Date.

 

(v)
               Mailing. If any Warrant Holder does
not wish to exercise any Warrant being redeemed, he should mail such Warrant to the Company at its principal offices after
receiving the notice of redemption. On and after 5:00 p.m. Eastern Time on the Redemption Date, notwithstanding that any
Warrant subject to redemption shall not have been surrendered for redemption, the obligation evidenced by all Warrants not
surrendered for redemption or effectively exercised shall be deemed no longer outstanding, and all rights with respect
thereto shall forthwith cease and terminate, except only the right of the holder of each Warrant subject to redemption to
receive the Redemption Price for each share of Common Stock to which he would be entitled if he exercised the Warrant upon
receiving notice of redemption of the Warrant subject to redemption held by him.

 

2.                 
Disposition of Warrant Stock and Warrant.

 

a.                  
The Holder hereby acknowledges that this Warrant and any Warrant Stock purchased pursuant hereto are, as of the date hereof, not
registered: (i) under the Securities Act of 1933, as amended (the “Securities Act”), on the ground that the issuance
of this Warrant is exempt from registration under Section 4(2) of the Securities Act as not involving any public offering or (ii)
under any applicable state securities law because the issuance of this Warrant does not involve any public offering; and that the
Company’s reliance on the Section 4(2) exemption of the Act, as the case may be, and under applicable state securities laws
is predicated in part on the representations hereby made to the Company by the Holder that it is acquiring this Warrant and will
acquire the Warrant Stock for investment for its own account, with no present intention of dividing its participation with others
or reselling or otherwise distributing the same, subject, nevertheless, to any requirement of law that the disposition of its property
shall at all times be within its control.

 

    	 

    	 

    

  

The Holder
hereby agrees that it will not sell or transfer all or any part of this Warrant and/or Warrant Stock unless and until it shall
first have given notice to the Company describing such sale or transfer and furnished to the Company either (i) an opinion, reasonably
satisfactory to counsel for the Company, of counsel (skilled in securities matters, selected by the Holder) to the effect that
the proposed sale or transfer may be made without registration under the Act and without registration or qualification under any
state law, or (ii) an interpretative letter from the Securities and Exchange Commission to the effect that no enforcement action
will be recommended if the proposed sale or transfer is made without registration under the Act.

 

b.                 
If, at the time of issuance of the shares issuable upon exercise of this Warrant, no registration statement is in effect with respect
to such shares under applicable provisions of the Act, the Company may at its election require that the Holder provide the Company
with written reconfirmation of the Holder’s investment intent and that any stock certificate delivered to the Holder of a
surrendered Warrant shall bear legends reading substantially as follows:

 

“THE SECURITIES REPRESENTED
BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE
IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”),
AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR
PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT
AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT,
THE SUBSTANCE OF WHICH SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY
BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.”

 

In addition, so long as the foregoing legend
may remain on any stock certificate delivered to the Holder, the Company may maintain appropriate “stop transfer” orders
with respect to such certificates and the shares represented thereby on its books and records and with those to whom it may delegate
registrar and transfer functions.

 

3.                 
Reservation of Shares. The Company hereby agrees that at all times there shall be reserved for issuance upon the exercise
of this Warrant such number of shares of its Common Stock as shall be required for issuance upon exercise of this Warrant. The
Company further agrees that all shares which may be issued upon the exercise of the rights represented by this Warrant will be
duly authorized and will, upon issuance and against payment of the exercise price, be validly issued, fully paid and non-assessable,
free from all taxes, liens, charges and preemptive rights with respect to the issuance thereof, other than taxes, if any, in respect
of any transfer occurring contemporaneously with such issuance and other than transfer restrictions imposed by federal and state
securities laws.

 

4.                 
Exchange, Transfer or Assignment of Warrant. This Warrant is exchangeable, without expense, at the option of the Holder,
upon presentation and surrender hereof to the Company or at the office of its stock transfer agent, if any, for other Warrants
of different denominations, entitling the Holder or Holders thereof to purchase in the aggregate the same number of shares of Common
Stock purchasable hereunder. Upon surrender of this Warrant to the Company or at the office of its stock transfer agent, if any,
with the Assignment Form annexed hereto duly executed and funds sufficient to pay any transfer tax, the Company shall, without
charge, execute and deliver a new Warrant in the name of the assignee named in such instrument of assignment and this Warrant shall
promptly be canceled. This Warrant may be divided or combined with other Warrants that carry the same rights upon presentation
hereof at the office of the Company or at the office of its stock transfer agent, if any, together with a written notice specifying
the names and denominations in which new Warrants are to be issued and signed by the Holder hereof.

 

    	 

    	 

    

  

5.                 
Capital Adjustments. This Warrant is subject to the following further provisions:

 

a.                  
Share Issuance. For so long as any Warrants remain outstanding, other than in connection with (i) full or partial consideration
in connection with a strategic merger, acquisition, consolidation or purchase of substantially all of the securities or assets
of a corporation or other entity which holders of such securities or debt are not at any time granted registration rights equal
to or greater than those granted to the Holder, (ii) the Company’s issuance of securities in connection with strategic license
agreements and other partnering arrangements so long as such issuances are not primarily for the purpose of raising capital and
which holders of such securities or debt are not at any time granted registration rights equal to or greater than those granted
to the Holder, (iii) the Company’s issuance of Common Stock or the issuances or grants of options to purchase Common Stock
to employees, directors, and consultants, pursuant to plans that have been approved by a majority of the stockholders and a majority
of the independent members of the board of directors of the Company or in existence as such plans are constituted on the date of
this Agreement, (iv) securities issued upon the exercise or exchange of or conversion of any securities exercisable or exchangeable
for or convertible into shares of Common Stock issued and outstanding on the date of this Warrant, (v) as a result of the exercise
of Warrants issued pursuant to the subscription agreement between Cell Source Ltd. (the Company’s subsidiary) and the parties
to such subscription agreement, (vi) the Company’s issuance of Common Stock or the issuances or grants of options to purchase
Common Stock to consultants and service providers provide the holders of at least a majority of the shares of Common Stock have
approved such issuance, (vii) up to 3,000,000 shares of Common Stock of the Company or options or warrants to purchase Common Stock
of the Company issuable pursuant to the subscription agreement between Cell Source Ltd. (the Company’s subsidiary) and the
parties to such subscription agreement, (viii) securities including Common Stock, options, and or warrants issued, issuable or
to be issued in connection with the certain Share Exchange Agreement between the Company, Cell Source Ltd. and the shareholders
of Cell Source Ltd. who are parties to such agreement and (ix) any and all securities required to be assumed by the Company by
the terms thereof as a result of any of the foregoing even if issued by a predecessor acquired in connection with a business combination,
merger or share exchange (collectively, the foregoing (i) through (ix) are “ Excepted Issuances ”), if the Company
shall issue any Common Stock except for the Excepted Issuances prior to the complete exercise of this Warrant, for a consideration
less than the Warrant Price that would be in effect at the time of such issuance, then, and thereafter successively upon each such
issuance, the Warrant Price shall be reduced to such other lower price for then outstanding Warrants. For purposes of this adjustment,
any agreement entered for or the issuance of any security or debt instrument of the Company carrying the right to convert such
security or debt instrument into Common Stock or of any warrant, right or option to purchase Common Stock shall result in an adjustment
to the Warrant Price upon the issuance of the above-described security, debt instrument, warrant, right, or option if such issuance
is at a price lower than the Warrant Price in effect upon such issuance and again at any time upon any actual, permitted, optional,
or allowed issuances of shares of Common Stock upon any actual, permitted, optional, or allowed exercise of such conversion or
purchase rights if such issuance is at a price lower than the Warrant Price in effect upon any actual, permitted, optional, or
allowed such issuance. Common Stock issued or issuable by the Company for no consideration will be deemed issuable or to have been
issued for $0.001 per share of Common Stock.

 

b.                 
Subdivision or Combination of Shares. If the Company at any time while this Warrant remains outstanding and unexpired shall
subdivide or combine its Common Stock, the number of shares of Warrant Stock purchasable upon exercise of this Warrant and the
Warrant Price shall be proportionately adjusted.

 

c.                  
Stock Dividends and Distributions. If the Company at any time while this Warrant is outstanding and unexpired shall issue
or pay the holders of its Common Stock, or take a record of the holders of its Common Stock for the purpose of entitling them to
receive, a dividend payable in, or other distribution of, Common Stock, then (i) the Warrant Price shall be adjusted in accordance
with Section 5(f) and (ii) the number of shares of Warrant Stock purchasable upon exercise of this Warrant shall be adjusted to
the number of shares of Common Stock that the Holder would have owned immediately following such action had this Warrant been exercised
immediately prior thereto.

 

d.                 
Stock and Rights Offering to Shareholders. If the Company shall at any time after the date of issuance of this Warrant distribute
to all holders of its Common Stock any shares of capital stock of the Company (other than Common Stock) or evidences of its indebtedness
or assets (excluding cash dividends or distributions paid from retained earnings or current year’s or prior year’s
earnings of the Company) or rights or warrants to subscribe for or purchase any of its securities (excluding those referred to
in the immediately preceding paragraph) (any of the foregoing being hereinafter in this paragraph called the “Securities”),
then in each such case, the Company shall reserve shares or other units of such Securities for distribution to the Holder upon
exercise of this Warrant so that, in addition to the shares of the Common Stock to which such Holder is entitled, such Holder will
receive upon such exercise the amount and kind of such Securities which such Holder would have received if the Holder had, immediately
prior to the record date for the distribution of the Securities, exercised this Warrant.

 

e.                  
Intentionally Omitted.

 

f.                  
Warrant Price Adjustment. Except as otherwise provided herein, whenever the number of shares of Warrant Stock purchasable
upon exercise of this Warrant is adjusted, as herein provided, the Warrant Price payable upon the exercise of this Warrant shall
be adjusted to that price determined by multiplying the Warrant Price immediately prior to such adjustment by a fraction (i) the
numerator of which shall be the number of shares of Warrant Stock purchasable upon exercise of this Warrant immediately prior to
such adjustment, and (ii) the denominator of which shall be the number of shares of Warrant Stock purchasable upon exercise of
this Warrant immediately thereafter.

 

g.                 
Certain Shares Excluded. The number of shares of Common Stock outstanding at any given time for purposes of the adjustments
set forth in this Section 5 shall exclude any shares then directly or indirectly held in the treasury of the Company.

 

h.                 
Deferral and Cumulation of De Minimis Adjustments. The Company shall not be required to make any adjustment pursuant to
this Section 5 if the amount of such adjustment would be less than one percent (1%) of the Warrant Price in effect immediately
before the event that would otherwise have given rise to such adjustment. In such case, however, any adjustment that would otherwise
have been required to be made shall be made at the time of and together with the next subsequent adjustment which, together with
any adjustment or adjustments so carried forward, shall amount to not less than one (1%) percent of the Warrant Price in effect
immediately before the event giving rise to such next subsequent adjustment.

 

i.                   
Duration of Adjustment. Following each computation or readjustment as provided in this Section 5, the new adjusted Warrant
Price and number of shares of Warrant Stock purchasable upon exercise of this Warrant shall remain in effect until a further computation
or readjustment thereof is required.

 

    	 

    	 

    

  

6.                 
Limitation on Exercises.

 

a.                 
Notwithstanding anything to the contrary set forth in this Warrant, at no time may all or a portion of the Warrant be exercised
if the number of shares of Common Stock to be issued pursuant to such exercise would exceed, when aggregated with all other shares
of Common Stock owned by the Holder at such time, the number of shares of Common Stock which would result in the Holder beneficially
owning (as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”) and the rules thereunder) more than 4.99% of all of the Common Stock outstanding at such time;  provided , 
however , that upon the Holder providing the Corporation with sixty-one (61) days’ advance notice (the “4.99% Waiver
Notice”) that the Holder would like to waive this Section 6 (a) with regard to any or all shares of Common Stock issuable
upon exercise of this Warrant, this Section 6 (a) will be of no force or effect with regard to all or a portion of this Warrant
referenced in the 4.99% Waiver Notice.

 

b.                
Notwithstanding anything to the contrary set forth in this Warrant, at no time may all or a portion of this Warrant be exercised
if the number of shares of Common Stock to be issued pursuant to such exercise, when aggregated with all other shares of Common
Stock owned by the Holder at such time, would result in the Holder beneficially owning (as determined in accordance with Section
13(d) of the Exchange Act and the rules thereunder) in excess of 9.99% of the then issued and outstanding shares of Common Stock
outstanding at such time (the “ 9.99% Beneficial Ownership Limitation ” and the lower of the 9.99% Beneficial
Ownership Limitation and the 4.99% Beneficial Ownership Limitation then in effect, the “ Maximum Percentage ”).

 

c.                 
By written notice to the Company, the Holder may from time to time decrease the Maximum Percentage to any other percentage specified
in such notice

 

d.                 
For purposes of this Warrant, in determining the number of outstanding shares of Common Stock, the Holder may rely on the number
of outstanding shares of Common Stock as reflected in (1) the Company's most recent Form 10-K, Form 10-Q, Current Report on Form
8-K or other public filing with the Securities and Exchange Commission, as the case may be, (2) a more recent public announcement
by the Company or (3) any other notice by the Company setting forth the number of shares of Common Stock outstanding. For any reason
at any time, upon the written or oral request of the Holder, the Company shall within one (1) business day confirm orally and in
writing to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common
Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant,
by the Holder and its affiliates since the date as of which such number of outstanding shares of Common Stock was reported. The
provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms
of this Section 6 to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended beneficial
ownership limitation herein contained or to make changes or supplements necessary or desirable to properly give effect to such
limitation.

 

7.                 
Notice to Holders.

 

a.                  
Notice of Record Date. In case:

 

(i)                
the Company shall take a record of the holders of its Common Stock (or other stock or securities at the time receivable upon the
exercise of this Warrant) for the purpose of entitling them to receive any dividend (other than a cash dividend payable out of
earned surplus of the Company) or other distribution, or any right to subscribe for or purchase any shares of stock of any class
or any other securities, or to receive any other right;

 

(ii)              
of any capital reorganization of the Company, any reclassification of the capital stock of the Company, any consolidation with
or merger of the Company into another corporation, or any conveyance of all or substantially all of the assets of the Company to
another corporation; or

 

(iii)            
of any voluntary dissolution, liquidation or winding-up of the Company;

 

then, and in each such case, the Company
will mail or cause to be mailed to the Holder hereof at the time outstanding a notice specifying, as the case may be, (i) the date
on which a record is to be taken for the purpose of such dividend, distribution or right, and stating the amount and character
of such dividend, distribution or right, or (ii) the date on which such reorganization, reclassification, consolidation, merger,
conveyance, dissolution, liquidation or winding-up is to take place, and the time, if any, is to be fixed, as of which the holders
of record of Common Stock (or such stock or securities at the time receivable upon the exercise of this Warrant) shall be
entitled to exchange their shares of Common Stock (or such other stock or securities) for securities or other property deliverable
upon such reorganization, reclassification, consolidation, merger, conveyance, dissolution or winding-up. Such notice shall be
mailed at least thirty (30) days prior to the record date therein specified, or if no record date shall have been specified therein,
at least thirty (30) days prior to such specified date, provided, however, failure to provide any such notice shall not affect
the validity of such transaction.

 

b.                 
Certificate of Adjustment. Whenever any adjustment shall be made pursuant to Section 5 hereof, the Company shall promptly
make a certificate signed by its Chairman, Chief Executive Officer, President, Vice President, Chief Financial Officer or Treasurer,
setting forth in reasonable detail the event requiring the adjustment, the amount of the adjustment, the method by which such adjustment
was calculated and the Warrant Price and number of shares of Warrant Stock purchasable upon exercise of this Warrant after
giving effect to such adjustment, and shall promptly cause copies of such certificates to be mailed (by first class mail, postage
prepaid) to the Holder of this Warrant.

 

    	 

    	 

    

  

8.                 
Loss, Theft, Destruction or Mutilation. Upon receipt by the Company of evidence satisfactory to it, in the exercise of its
reasonable discretion, of the ownership and the loss, theft, destruction or mutilation of this Warrant and, in the case of loss,
theft or destruction, of indemnity reasonably satisfactory to the Company and, in the case of mutilation, upon surrender and cancellation
thereof, the Company will execute and deliver in lieu thereof, without expense to the Holder, a new Warrant of like tenor dated
the date hereof.

 

9.                 
Warrant Holder Not a Stockholder. The Holder of this Warrant, as such, shall not be entitled by reason of this Warrant to
any rights whatsoever as a stockholder of the Company.

 

10.             
Notices. Any notice required or contemplated by this Warrant shall be deemed to have been duly given if transmitted by registered
or certified mail, return receipt requested, or nationally recognized overnight delivery service, to the Company at its
principal executive offices located at ______, Attn: Chief Executive Officer, or to the Holder at the name and address set forth
in the Warrant Register maintained by the Company.

 

11.             
Choice of Law. THIS WARRANT IS ISSUED UNDER AND SHALL FOR ALL PURPOSES BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE
INTERNAL LAWS OF THE STATE OF NEW YORK, WITHOUT GIVING EFFECT TO PRINCIPLES OF CONFLICTS OF LAW.

 

12.             
Jurisdiction and Venue. The Company and Holder hereby agree that any dispute which may arise between them arising out of
or in connection with this Warrant shall be adjudicated before a court located in New York County, New York and they hereby submit
to the exclusive jurisdiction of the federal and state courts of the State of York located in New York County with respect to any
action or legal proceeding commenced by any party, and irrevocably waive any objection they now or hereafter may have respecting
the venue of any such action or proceeding brought in such a court or respecting the fact that such court is an inconvenient forum,
relating to or arising out of this Warrant or any acts or omissions relating to the sale of the securities hereunder, and consent
to the service of process in any such action or legal proceeding by means of registered or certified mail, return receipt requested,
in care of the address set forth herein or such other address as either party shall furnish in writing to the other.

 

13.             
Amendment. This Warrant may be modified or amended or the provisions hereof waived with the written consent signed by both
(a) the Company and (b) holders of Warrants representing a majority of the Warrant Stock then outstanding and not exercised

 

[Signature Page Follows]

 

    	 

    	 

    

  

IN WITNESS WHEREOF,
the Company has duly caused this Warrant to be signed on its behalf, in its corporate name and by its duly authorized officers,
as of this __ day of _____________________, 2014.

 

	 	 	By:	 
	 	Name:	 
	 	Title: 	 

 

    	 

    	 

    

  

NOTICE OF EXERCISE

TO:

Tel: (___) ___-____

Fax: (___) ___-____

 

(1)              
The undersigned hereby elects to purchase ______________ shares of Warrant Stock of the Company pursuant to the terms of the attached
Warrant to Purchase Common Stock, and tenders herewith payment of the exercise price in full, together with all applicable transfer
taxes, if any.

 

(2)              
Payment shall take the form of:

 

£      in
lawful money of the United States

 

Please issue a certificate or
certificates representing said shares of Warrant Stock in the name of the undersigned or in such other name as is specified below:

 

 

 

The shares of Warrant
Stock shall be delivered to the following DWAC Account Number, if permitted, or by physical delivery of a certificate to:

 

 

 

(3)              
Accredited Investor. The undersigned is an “accredited investor” as defined in Regulation D promulgated under
the Securities Act of 1933, as amended.

 

[SIGNATURE OF HOLDER]

 

Name of Investing Entity:

 

Signature of Authorized Signatory of Investing Entity:

 

Name and Title of Authorized Signatory:

 

Date:

 

    	 

    	 

    

  

ASSIGNMENT FORM

 

(To assign the foregoing warrant, execute

this form and supply
required information.

Do not use this form
to exercise the warrant.)

 

FOR VALUE RECEIVED,
all of or _________ shares of the foregoing Warrant and all rights evidenced thereby are hereby assigned to

 

________________________________whose address is

_____________________________________________

_____________________________________________

 

Dated: _________,         

Holder’s Name:

 

Holder’s Signature:

 

Name and Title of Signatory:

 

Holder’s Address:

 

Signature Guaranteed:

 

NOTE: The signature to this Assignment
Form must correspond with the name as it appears on the face of the Warrant, without alteration or enlargement or any change whatsoever,
and must be guaranteed by a bank or trust company. Officers of corporations and those acting in a fiduciary or other representative
capacity should file proper evidence of authority to assign the foregoing Warrant.EX-10.1

 Exhibit 10.1 

SECURITIES PURCHASE AGREEMENT 

This Securities Purchase Agreement (this “Agreement”) is made and entered into as of June 26th, 2014, by and between International Stem Cell Corporation, a Delaware corporation (the “Company”), and the investors listed on the signature page hereof (individually a
“Purchaser” and collectively, the “Purchasers”). 
 RECITALS 

WHEREAS, the Company desires to sell to the Purchasers, and the Purchasers desire to purchase from the Company, on the terms and conditions
set forth in this Agreement, 5,500,000 shares (the “Shares”) of common stock, par value $0.001 per share, of the Company (the “Common Stock”); 

WHEREAS, the Purchasers are executive officers and directors of the Company; 

WHEREAS, each Purchaser is knowledgeable about (i) the Company’s business, financial condition, results of operations, prospects and
risks, (ii) any recent developments related thereto, and (iii) the filings made by the Company with the Securities and Exchange Commission (the “SEC”) under the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), and the information contained therein. 
 NOW, THEREFORE, in consideration of the foregoing, the
mutual promises hereinafter set forth, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 

1. AGREEMENT TO PURCHASE AND SELL SECURITIES. 

(a) Subject to the terms and conditions of this Agreement, the Company shall sell to the Purchasers the respective number of Shares set forth
on the signature page hereof. The purchase price of each Share shall be $0.10. 
 2. CLOSING.  

(a) The purchase and sale of the Shares shall take place at the Company’s principal executive offices, 5950 Priestly Drive, Carlsbad,
California 92008, upon execution of this Agreement (which time and place are referred to in this Agreement as the “Closing”). 

(b) At the Closing, against delivery of full payment for the Shares sold hereunder by check payable to the Company or by wire transfer of
immediately available funds in accordance with the Company’s instructions, the Company shall (i) issue and deliver or cause to be delivered to each Purchaser one or more stock certificates registered in the name of Purchaser or
(ii) arrange for the book-entry transfer of the Shares, all of which Shares shall bear the legend set forth in Section 4(e) below; provided, however, that in lieu of delivery of the Shares at the Closing, the Company may
furnish to the Purchasers a copy of the irrevocable instructions to the Company’s transfer agent instructing the transfer agent to deliver a certificate or certificates evidencing, or arrange for the book-entry transfer of, the Shares,
registered in the name of the Purchasers. 

  
 1 

 3. REPRESENTATIONS AND WARRANTIES OF THE COMPANY. The Company hereby represents and
warrants to each Purchaser that: 
 (a) Due Authorization. All corporate actions on the part of the Company necessary for the
authorization, execution, delivery of, and the performance of all obligations of the Company under this Agreement, including the authorization, issuance, and delivery of the Shares, have been taken and no further consent or authorization of the
Company, the Board of Directors of the Company or the Company’s stockholders is required. This Agreement constitutes the legal, valid and binding obligation of the Company, enforceable against the Company in accordance with its terms, except as
may be limited by (i) applicable bankruptcy, insolvency, reorganization or other laws of general application relating to or affecting the enforcement of creditors’ rights generally, and (ii) the effect of rules of law governing the
availability of equitable remedies. 
 (b) Valid Issuance of the Shares. When issued at the Closing, the Shares will be, duly
authorized, validly issued, fully paid and non-assessable, free and clear from all taxes and liens, claims and encumbrances imposed by the Company, other than restrictions under applicable securities laws, and will not be subject to any preemptive
rights or similar rights that have not been waived by the holders thereof. 
 (c) Exchange Act Documents. The Company has filed all
reports, schedules, statements and other documents required to be filed by it with the SEC pursuant to the reporting requirements of the Exchange Act and the rules and regulations promulgated thereunder (the “Exchange Act
Documents”). Each of the Exchange Act Documents, as of the respective dates thereof (or, if amended or superseded by a filing or submission, as the case may be, prior to the Closing, then on the date of such filing or submission, as the
case may be), (1) did not contain any untrue statement of a material fact nor omit to state a material fact necessary in order to make the statements made therein, in light of the circumstances under which they were made, not misleading and
(2) complied in all material respects with the requirements of the Exchange Act and the rules and regulations of the SEC promulgated thereunder applicable to such Exchange Act Document. 

4. REPRESENTATIONS AND WARRANTIES OF EACH PURCHASER. Each Purchaser, separately and not jointly hereby represents and warrants
to the Company that: 
 (a) Due Authorization. All action on the part of the Purchaser necessary for the authorization, execution,
delivery of and the performance of the transactions contemplated by this Agreement have been taken and no further consent or authorization of the Purchaser is necessary. This Agreement, when delivered by the Purchaser in accordance with the terms
hereof, will constitute Purchaser’s legal, valid and binding obligation, enforceable in accordance with its terms, except as may be limited by (i) applicable bankruptcy, insolvency, reorganization or other laws of general application
relating to or affecting the enforcement of creditors’ rights generally and (ii) the effect of rules of law governing the availability of equitable remedies. 

(b) Purchase for Own Account. The Securities are being acquired for investment for the Purchaser’s own account, not as a nominee
or agent, in the ordinary course of business, and not with a view to the public resale or distribution thereof within the meaning of the Securities Act of 1933, as amended. The Purchaser does not have any agreement or understanding, direct or
indirect, with any other person to sell or otherwise distribute the Securities. Notwithstanding the foregoing, the parties hereto acknowledge the Purchaser’s right at all times to sell or otherwise dispose of all or any part of the Securities
in compliance with applicable federal and state securities laws and as otherwise contemplated by this Agreement. 
 (c) Investment
Experience and Knowledge of the Company. The Purchaser understands that the purchase of the Securities involves substantial risk. The Purchaser has experience as an investor in securities of the Company and companies similar to the Company and
acknowledges that he can bear the economic risk of his investment in the Shares and has such knowledge and experience in 

  
 2 

 
financial or business matters that he is capable of evaluating the merits and risks of this investment in the Shares and protecting his own interests in connection with this investment. The
Purchaser is fully informed of the Company’s business, financial condition, results of operation, prospects and risks. 
 (d)
Restricted Securities and Restrictions on Transfer. 
 (i) The Purchaser understands that the Securities have not
been registered under the Securities Act and the Purchaser agrees that he will not sell, offer to sell, assign, pledge, hypothecate or otherwise transfer any of the Securities (except as permitted in Section 4(d)(iii) below) unless
(1) pursuant to an effective registration statement under the Securities Act, (2) the Purchaser provides a reasonably acceptable legal opinion to the Company, to the effect that a sale, assignment, pledge, hypothecation or other transfer
of the Securities may be made without registration under the Securities Act, (3) the Purchaser provides the Company a “no action” letter from the SEC to the effect that the transfer of the Securities without registration will not
result in a recommendation by the Staff of the SEC that enforcement action be taken with respect thereto, (4) the Purchaser provides the Company with reasonable assurances (in the form of seller and broker representation letters) that the
Securities can be sold pursuant to Rule 144 promulgated under the Securities Act (“Rule 144”), or (5) pursuant to any other exception contained in the Securities Act provided that the Purchaser provides a reasonably
acceptable legal opinion to the Company. 
 (ii) Prior to any proposed transfer pursuant to clause (2), (3), (4) or
(5) in Section 4(d)(i) above, the Purchaser shall give written notice to the Company of such Purchaser’s intention to effect such transfer. Each such notice shall describe the manner and circumstances of the proposed transfer
in sufficient detail, and shall be accompanied by the applicable legal opinion, “no action” letter or seller and broker representation letters. 

(iii) Notwithstanding the foregoing provisions of this Section 4(d), no registration statement, legal opinion or
“no action” letter shall be necessary for a transfer of the Shares by gift, will or intestate succession to the Purchaser’s spouse or other immediate family members. 

(e) Legends. Purchaser agrees that, to the extent necessary, the certificates representing the Shares, the Warrant and the Warrant
Shares shall bear substantially the following legends: 
 (i) “THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE
SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THESE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE
SECURITIES UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS, UNLESS SOLD PURSUANT TO: (1) RULE 144 UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR (2) AN OPINION OF HOLDER’S COUNSEL, IN A CUSTOMARY
FORM, THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR APPLICABLE STATE SECURITIES LAWS.” 
 (ii) Any other legend
required to be placed thereon by applicable state or federal laws. 

  
 3 

 5. MISCELLANEOUS. 

(a) Successors and Assigns. The terms and conditions of this Agreement will inure to the benefit of and be binding upon the respective
successors and permitted assigns of the parties. The Company shall not assign this Agreement or any rights or obligations hereunder without the prior written consent of the Purchasers. Each Purchaser may assign its rights under this Agreement to any
person to whom such Purchaser assigns or transfers any of the Shares, provided that such transferee agrees in writing to be bound by the terms and provisions of this Agreement, and such transfer is in compliance with the terms and provisions of this
Agreement and permitted by federal and state securities laws. 
 (b) Governing Law. This Agreement will be governed by and construed
and enforced under the internal laws of the State of Delaware, without reference to principles of conflict of laws or choice of laws. 
 (c)
Survival. The representations and warranties of the Company contained in Section 3 of this Agreement and of the Purchaser contained in Section 4 of this Agreement shall survive the Closing. 

(d) Counterparts. This Agreement may be executed counterparts, each of which will be deemed an original, but all of which together will
constitute one and the same instrument. 
 (e) Headings. The headings and captions used in this Agreement are used for convenience
only and are not to be considered in construing or interpreting this Agreement. 
 (f) Notices. Any notices and other communications
required or permitted under this Agreement shall be in writing and shall be delivered (i) personally by hand or by courier, (ii) mailed by United States first-class mail, postage prepaid or (iii) sent by facsimile or other electronic
transmission directed to the address or facsimile number or other address for electronic transmission set forth below. All such notices and other communications shall be deemed given upon (i) receipt or refusal of receipt, if delivered
personally, (ii) three (3) days after being placed in the mail, if mailed, or (iii) confirmation of facsimile transfer or other electronic transmission, if faxed. 

If to the Company: 

International Stem Cell Corporation. 

5950 Priestly Drive, Carlsbad, California 92008 

Tel: (760) 940-6383 
 Fax:
(760) 476-0600 
 Attention: Chief Financial Officer 

with a copy to: 
 DLA Piper LLP
(US) 
 4365 Executive Drive, Suite 1100 

San Diego, California 92121 

Tel: (858) 677-1400 
 Fax:
(858) 638-5043 
 Attention: Douglas Rein 

If to a Purchaser: 
 5950
Priestly Drive, Carlsbad, California 92008 
 Attn: Dr. R. Semechkin 

  
 4 

 With a copy to: 

McLane, Graf, Raulerson & Middleton, Professional Association 

City Hall Plaza – 900 Elm Street 

P.O. Box 326 
 Manchester, New
Hampshire 03105-0326 
 Attn. Michael B. Tule, Esq. 

Tel. (603) 628-1290 
 Fax:
(603) 625 5650 
 (g) Amendments and Waivers. This Agreement may be amended and the observance of any term of this Agreement may
be waived only with the written consent of the Company and the Purchasers. Any amendment effected in accordance with this Section 5(g) will be binding upon all Purchasers, the Company and their respective successors and assigns. 

(h) Severability. If any provision of this Agreement is held to be unenforceable under applicable law, such provision will be excluded
from this Agreement and the balance of the Agreement will be interpreted as if such provision were so excluded and will be enforceable in accordance with its terms. 

(i) Entire Agreement. This Agreement, together with all exhibits and schedules thereto, constitutes the entire agreement and
understanding of the parties with respect to the subject matter hereof and thereof and supersede any and all prior negotiations, correspondence, agreements, understandings, duties or obligations between the parties with respect to the subject matter
hereof and thereof. 
 (j) Fees, Costs and Expenses. All fees, costs and expenses (including attorneys’ fees and expenses)
incurred by any party hereto in connection with the preparation, negotiation and execution of this Agreement and the exhibits and schedules thereto and the consummation of the transactions contemplated hereby and thereby (including the costs
associated with any filings with, or compliance with any of the requirements of any governmental authorities), shall be the sole and exclusive responsibility of such party. 

(k) Waivers. No waiver by any party to this Agreement of any default with respect to any provision, condition or requirement of this
Agreement shall be deemed to be a continuing waiver in the future or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of
any such right accruing to it thereafter. 

  
 5 

 (l) Remedies. In addition to being entitled to exercise all rights provided herein or
granted by law, including recovery of damages, the Purchasers and the Company will be entitled to specific performance under this Agreement. The parties agree that monetary damages may not be adequate compensation for any loss incurred by reason of
any breach of obligations described in the foregoing sentence and hereby agree to waive in any action for specific performance of any such obligation the defense that a remedy at law would be adequate. 

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date and year first above written. 

 

					
	INTERNATIONAL STEM CELL CORPORATION
		
	By:	 	     /s/ Jay Novak

		 	Name:	 	Jay Novak
		 	Title:	 	Chief Financial Officer

 PURCHASERS: 
  

					
	 Andrey Semechkin
	  	 	4,800,000 shares	  

  

			
	 By:
	 	     /s/ Andrey Semechkin

	Andrey Semechkin

 c/o International Stem Cell Corporation 

5950 Priestly Drive, Carlsbad, California 92008 
 Tel:
(760) 940-6383 
 Fax: (760) 476-0600 
  

					
	 Ruslan Semechkin
	  	 	700,000 shares	  

  

			
	
	By:	 	     /s/ Ruslan Semechkin

	Ruslan Semechkin

 c/o International Stem Cell Corporation 

5950 Priestly Drive, Carlsbad, California 92008 
 Tel:
(760) 940-6383 
 Fax: (760) 476-0600 

  
 6

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}]]